{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T01:57:04Z","timestamp":1792634224527,"version":"4.5.0"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2017,12,15]],"date-time":"2017-12-15T00:00:00Z","timestamp":1513296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2017,12,15]],"date-time":"2017-12-15T00:00:00Z","timestamp":1513296000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Djibouti is a small country in the Horn of Africa with a high TB incidence (378\/100,000 in 2015). Multidrug-resistant TB (MDR-TB) and resistance to second-line agents have been previously identified in the country but the extent of the problem has yet to be quantified. A national survey was conducted to estimate the proportion of MDR-TB among a representative sample of TB patients. Sputum was tested using XpertMTB\/RIF and samples positive for MTB and resistant to rifampicin underwent first line phenotypic susceptibility testing. The TB supranational reference laboratory in Milan, Italy, undertook external quality assurance, genotypic testing based on whole genome and targeted-deep sequencing and phylogenetic studies. 301 new and 66 previously treated TB cases were enrolled. MDR-TB was detected in 34 patients: 4.7% of new and 31% of previously treated cases. Resistance to pyrazinamide, aminoglycosides and capreomycin was detected in 68%, 18% and 29% of MDR-TB strains respectively, while resistance to fluoroquinolones was not detected. Cluster analysis identified transmission of MDR-TB as a critical factor fostering drug resistance in the country. Levels of MDR-TB in Djibouti are among the highest on the African continent. High prevalence of resistance to pyrazinamide and second-line injectable agents have important implications for treatment regimens.<\/jats:p>","DOI":"10.1038\/s41598-017-17705-3","type":"journal-article","created":{"date-parts":[[2017,12,11]],"date-time":"2017-12-11T15:36:55Z","timestamp":1513006615000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":40,"title":["Culture and Next-generation sequencing-based drug susceptibility testing unveil high levels of drug-resistant-TB in Djibouti: results from the first national survey"],"prefix":"10.1038","volume":"7","author":[{"given":"Elisa","family":"Tagliani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed Osman","family":"Hassan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yacine","family":"Waberi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Rosaria","family":"De Filippo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dennis","family":"Falzon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Dean","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Zignol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip","family":"Supply","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed Ali","family":"Abdoulkader","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hawa","family":"Hassangue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela Maria","family":"Cirillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,12,15]]},"reference":[{"key":"17705_CR1","unstructured":"World Health Organization. Global tuberculosis report, 2016. 20th ed. Geneva, Switzerland: WHO, 2016. (WHO, Geneva, Switzerland, 2016)."},{"key":"17705_CR2","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1056\/NEJMsr1512438","volume":"375","author":"M Zignol","year":"2016","unstructured":"Zignol, M. et al. Twenty Years of Global Surveillance of Antituberculosis-Drug Resistance. N Engl J Med \n                           375, 1081\u20131089, https:\/\/doi.org\/10.1056\/NEJMsr1512438 (2016).","journal-title":"N Engl J Med"},{"key":"17705_CR3","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.cmi.2016.10.014","volume":"23","author":"TM Walker","year":"2017","unstructured":"Walker, T. M. et al. Whole genome sequencing for M\/XDR tuberculosis surveillance and for resistance testing. Clin Microbiol Infect \n                           23, 161\u2013166, https:\/\/doi.org\/10.1016\/j.cmi.2016.10.014 (2017).","journal-title":"Clin Microbiol Infect"},{"key":"17705_CR4","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1093\/jac\/dkt042","volume":"68","author":"S Feuerriegel","year":"2013","unstructured":"Feuerriegel, S., K\u00f6ser, C. U., Richter, E. & Niemann, S. Mycobacterium canettii is intrinsically resistant to both pyrazinamide and pyrazinoic acid. J Antimicrob Chemother \n                           68, 1439\u20131440, https:\/\/doi.org\/10.1093\/jac\/dkt042 (2013).","journal-title":"J Antimicrob Chemother"},{"key":"17705_CR5","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1038\/ng.2656","volume":"45","author":"CB Ford","year":"2013","unstructured":"Ford, C. B. et al. Mycobacterium tuberculosis mutation rate estimates from different lineages predict substantial differences in the emergence of drug-resistant tuberculosis. Nat Genet \n                           45, 784\u2013790, https:\/\/doi.org\/10.1038\/ng.2656 (2013).","journal-title":"Nat Genet"},{"key":"17705_CR6","doi-asserted-by":"publisher","first-page":"660","DOI":"10.3201\/eid1804.110912","volume":"18","author":"JE de Steenwinkel","year":"2012","unstructured":"de Steenwinkel, J. E. et al. Drug susceptibility of Mycobacterium tuberculosis Beijing genotype and association with MDR TB. Emerg Infect Dis \n                           18, 660\u2013663, https:\/\/doi.org\/10.3201\/eid1804.110912 (2012).","journal-title":"Emerg Infect Dis"},{"key":"17705_CR7","unstructured":"World Health Organization. Expand-TB project: Progress in diagnosis. Geneva, Switzerland: WHO, 2014. http:\/\/www.who.int\/tb\/publications\/factsheet_expand_tb.pdf (WHO, Geneva, Switzerland, 2014)."},{"key":"17705_CR8","doi-asserted-by":"publisher","first-page":"478","DOI":"10.3201\/eid1903.121287","volume":"19","author":"I Sindani","year":"2013","unstructured":"Sindani, I. et al. Multidrug-resistant tuberculosis, Somalia, 2010\u20132011. Emerg Infect Dis \n                           19, 478\u2013480, https:\/\/doi.org\/10.3201\/eid1903.121287 (2013).","journal-title":"Emerg Infect Dis"},{"key":"17705_CR9","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1128\/AAC.49.2.571-577.2005","volume":"49","author":"CE Maus","year":"2005","unstructured":"Maus, C. E., Plikaytis, B. B. & Shinnick, T. M. Mutation of tlyA confers capreomycin resistance in Mycobacterium tuberculosis. Antimicrob Agents Chemother \n                           49, 571\u2013577, https:\/\/doi.org\/10.1128\/AAC.49.2.571-577.2005 (2005).","journal-title":"Antimicrob Agents Chemother"},{"key":"17705_CR10","doi-asserted-by":"publisher","first-page":"e01819","DOI":"10.1128\/mBio.01819-14","volume":"5","author":"P Miotto","year":"2014","unstructured":"Miotto, P. et al. Mycobacterium tuberculosis pyrazinamide resistance determinants: a multicenter study. MBio \n                           5, e01819\u201301814, https:\/\/doi.org\/10.1128\/mBio.01819-14 (2014).","journal-title":"MBio"},{"key":"17705_CR11","doi-asserted-by":"publisher","first-page":"e0133869","DOI":"10.1371\/journal.pone.0133869","volume":"10","author":"MG Whitfield","year":"2015","unstructured":"Whitfield, M. G. et al. A Global Perspective on Pyrazinamide Resistance: Systematic Review and Meta-Analysis. PLoS One \n                           10, e0133869, https:\/\/doi.org\/10.1371\/journal.pone.0133869 (2015).","journal-title":"PLoS One"},{"key":"17705_CR12","doi-asserted-by":"publisher","DOI":"10.1038\/emi.2013.38","volume":"2","author":"S Zhang","year":"2013","unstructured":"Zhang, S. et al. Mutations in panD encoding aspartate decarboxylase are associated with pyrazinamide resistance in Mycobacterium tuberculosis. Emerg Microbes Infect \n                           2, e34, https:\/\/doi.org\/10.1038\/emi.2013.38 (2013).","journal-title":"Emerg Microbes Infect"},{"key":"17705_CR13","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms5812","volume":"5","author":"F Coll","year":"2014","unstructured":"Coll, F. et al. A robust SNP barcode for typing Mycobacterium tuberculosis complex strains. Nat Commun \n                           5, 4812, https:\/\/doi.org\/10.1038\/ncomms5812 (2014).","journal-title":"Nat Commun"},{"key":"17705_CR14","unstructured":"World Health Organization. Guidelines for surveillance of drug resistance in tuberculosis. 5th ed. Geneva, Switzerland: WHO, 2015. (WHO, Geneva, Switzerland, 2015)."},{"key":"17705_CR15","unstructured":"Programme National de Lutte Anti-Tuberculeuse. Guide Technique de Lutte Anti-Tuberculeuse 2014, https:\/\/www.slideshare.net\/abdillahidoualehmaha\/guide-lat-djibouti-nov2014."},{"key":"17705_CR16","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1016\/S1473-3099(16)30190-6","volume":"16","author":"M Zignol","year":"2016","unstructured":"Zignol, M. et al. Population-based resistance of Mycobacterium tuberculosis isolates to pyrazinamide and fluoroquinolones: results from a multicountry surveillance project. Lancet Infect Dis \n                           16, 1185\u20131192, https:\/\/doi.org\/10.1016\/S1473-3099(16)30190-6 (2016).","journal-title":"Lancet Infect Dis"},{"key":"17705_CR17","doi-asserted-by":"crossref","unstructured":"Ngabonziza, J. C. S. et al. Half of rifampicin-resistant Mycobacterium tuberculosis complex isolated from tuberculosis patients in Sub-Saharan Africa have concomitant resistance to pyrazinamide. PLOS ONE \n                           12(10), e0187211 (2017).","DOI":"10.1371\/journal.pone.0187211"},{"key":"17705_CR18","doi-asserted-by":"publisher","unstructured":"Dheda, K. et al. The epidemiology, pathogenesis, transmission, diagnosis, and management of multidrug-resistant, extensively drug-resistant, and incurable tuberculosis. Lancet Respir Med, https:\/\/doi.org\/10.1016\/S2213-2600(17)30079-6 (2017).","DOI":"10.1016\/S2213-2600(17)30079-6"},{"key":"17705_CR19","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1016\/S2213-2600(15)00458-0","volume":"3","author":"EA Kendall","year":"2015","unstructured":"Kendall, E. A., Fofana, M. O. & Dowdy, D. W. Burden of transmitted multidrug resistance in epidemics of tuberculosis: a transmission modelling analysis. Lancet Respir Med \n                           3, 963\u2013972, https:\/\/doi.org\/10.1016\/S2213-2600(15)00458-0 (2015).","journal-title":"Lancet Respir Med"},{"key":"17705_CR20","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.diabres.2014.06.011","volume":"106","author":"BI Restrepo","year":"2014","unstructured":"Restrepo, B. I. & Schlesinger, L. S. Impact of diabetes on the natural history of tuberculosis. Diabetes Res Clin Pract \n                           106, 191\u2013199, https:\/\/doi.org\/10.1016\/j.diabres.2014.06.011 (2014).","journal-title":"Diabetes Res Clin Pract"},{"key":"17705_CR21","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.tube.2017.01.006","volume":"103","author":"LM Perez-Navarro","year":"2017","unstructured":"Perez-Navarro, L. M. et al. The effect size of type 2 diabetes mellitus on tuberculosis drug resistance and adverse treatment outcomes. Tuberculosis (Edinb) \n                           103, 83\u201391, https:\/\/doi.org\/10.1016\/j.tube.2017.01.006 (2017).","journal-title":"Tuberculosis (Edinb)"},{"key":"17705_CR22","doi-asserted-by":"publisher","first-page":"1514","DOI":"10.1378\/chest.120.5.1514","volume":"120","author":"M Bashar","year":"2001","unstructured":"Bashar, M., Alcabes, P., Rom, W. N. & Condos, R. Increased incidence of multidrug-resistant tuberculosis in diabetic patients on the Bellevue Chest Service, 1987 to 1997. Chest \n                           120, 1514\u20131519 (2001).","journal-title":"Chest"},{"key":"17705_CR23","doi-asserted-by":"publisher","first-page":"e404","DOI":"10.1016\/j.ijid.2012.12.029","volume":"17","author":"MJ Magee","year":"2013","unstructured":"Magee, M. J. et al. Clinical characteristics, drug resistance, and treatment outcomes among tuberculosis patients with diabetes in Peru. Int J Infect Dis \n                           17, e404\u2013412, https:\/\/doi.org\/10.1016\/j.ijid.2012.12.029 (2013).","journal-title":"Int J Infect Dis"},{"key":"17705_CR24","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1086\/507543","volume":"43","author":"HM Nijland","year":"2006","unstructured":"Nijland, H. M. et al. Exposure to rifampicin is strongly reduced in patients with tuberculosis and type 2 diabetes. Clin Infect Dis \n                           43, 848\u2013854, https:\/\/doi.org\/10.1086\/507543 (2006).","journal-title":"Clin Infect Dis"},{"key":"17705_CR25","doi-asserted-by":"publisher","first-page":"151","DOI":"10.5588\/ijtld.14.0200","volume":"19","author":"SM Kamal","year":"2015","unstructured":"Kamal, S. M. et al. Anti-tuberculosis drug resistance in Bangladesh: reflections from the first nationwide survey. Int J Tuberc Lung Dis \n                           19, 151\u2013156, https:\/\/doi.org\/10.5588\/ijtld.14.0200 (2015).","journal-title":"Int J Tuberc Lung Dis"},{"key":"17705_CR26","doi-asserted-by":"publisher","first-page":"e0149806","DOI":"10.1371\/journal.pone.0149806","volume":"11","author":"P Aia","year":"2016","unstructured":"Aia, P. et al. The Burden of Drug-Resistant Tuberculosis in Papua New Guinea: Results of a Large Population-Based Survey. PLoS One \n                           11, e0149806, https:\/\/doi.org\/10.1371\/journal.pone.0149806 (2016).","journal-title":"PLoS One"},{"key":"17705_CR27","doi-asserted-by":"publisher","first-page":"448","DOI":"10.5588\/ijtld.15.0645","volume":"20","author":"S Tahseen","year":"2016","unstructured":"Tahseen, S. et al. Use of Xpert(\u00ae) MTB\/RIF assay in the first national anti-tuberculosis drug resistance survey in Pakistan. Int J Tuberc Lung Dis \n                           20, 448\u2013455, https:\/\/doi.org\/10.5588\/ijtld.15.0645 (2016).","journal-title":"Int J Tuberc Lung Dis"},{"key":"17705_CR28","unstructured":"World Health Organization. Implementing the End TB Strategy: the essentials (WHO\/HTM\/TB\/2015.31). Geneva, World Health Organization. 2015. http:\/\/www.who.int\/tb\/publications\/2015\/end_tb_essential.pdf."},{"key":"17705_CR29","unstructured":"World Health Organization. 2012. Tuberculosis laboratory biosafety manual. http:\/\/apps.who.int\/iris\/bitstream\/10665\/77949\/1\/9789241504638_eng.pdf?ua=1."},{"key":"17705_CR30","unstructured":"DNA Genotek. Product Data Sheet PD-PR-00596, Issue 1\/2016-07 http:\/\/www.dnagenotek.com\/US\/pdf\/PD-PR-00596.pdf (2015)."},{"key":"17705_CR31","doi-asserted-by":"crossref","first-page":"2578","DOI":"10.1128\/jcm.29.11.2578-2586.1991","volume":"29","author":"D van Soolingen","year":"1991","unstructured":"van Soolingen, D., Hermans, P. W., de Haas, P. E., Soll, D. R. & van Embden, J. D. Occurrence and stability of insertion sequences in Mycobacterium tuberculosis complex strains: evaluation of an insertion sequence-dependent DNA polymorphism as a tool in the epidemiology of tuberculosis. J Clin Microbiol \n                           29, 2578\u20132586 (1991).","journal-title":"J Clin Microbiol"},{"key":"17705_CR32","doi-asserted-by":"publisher","first-page":"5267","DOI":"10.1128\/AAC.00204-15","volume":"59","author":"SM Ramirez-Busby","year":"2015","unstructured":"Ramirez-Busby, S. M. & Valafar, F. Systematic review of mutations in pyrazinamidase associated with pyrazinamide resistance in Mycobacterium tuberculosis clinical isolates. Antimicrob Agents Chemother \n                           59, 5267\u20135277, https:\/\/doi.org\/10.1128\/AAC.00204-15 (2015).","journal-title":"Antimicrob Agents Chemother"},{"key":"17705_CR33","doi-asserted-by":"publisher","first-page":"1908","DOI":"10.1128\/JCM.00025-15","volume":"53","author":"S Feuerriegel","year":"2015","unstructured":"Feuerriegel, S. et al. PhyResSE: a Web Tool Delineating Mycobacterium tuberculosis Antibiotic Resistance and Lineage from Whole-Genome Sequencing Data. J Clin Microbiol \n                           53, 1908\u20131914, https:\/\/doi.org\/10.1128\/JCM.00025-15 (2015).","journal-title":"J Clin Microbiol"},{"key":"17705_CR34","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1164\/rccm.201510-2091OC","volume":"194","author":"MR Farhat","year":"2016","unstructured":"Farhat, M. R. et al. Genetic Determinants of Drug Resistance in Mycobacterium tuberculosis and Their Diagnostic Value. Am J Respir Crit Care Med \n                           194, 621\u2013630, https:\/\/doi.org\/10.1164\/rccm.201510-2091OC (2016).","journal-title":"Am J Respir Crit Care Med"},{"key":"17705_CR35","unstructured":"Miotto et al. A standardised method for interpreting the association between mutations and phenotypic drug-resistance in Mycobacterium tuberculosis. European Respiratory Journal, Article in press."},{"key":"17705_CR36","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/S1473-3099(12)70277-3","volume":"13","author":"TM Walker","year":"2013","unstructured":"Walker, T. M. et al. Whole-genome sequencing to delineate Mycobacterium tuberculosis outbreaks: a retrospective observational study. Lancet Infect Dis \n                           13, 137\u2013146, https:\/\/doi.org\/10.1016\/S1473-3099(12)70277-3 (2013).","journal-title":"Lancet Infect Dis"},{"key":"17705_CR37","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2105-11-379","volume":"11","author":"R Helaers","year":"2010","unstructured":"Helaers, R. & Milinkovitch, M. C. MetaPIGAv2.0: maximum likelihood large phylogeny estimation using the metapopulation genetic algorithm and other stochastic heuristics. BMC Bioinformatics \n                           11, 379, https:\/\/doi.org\/10.1186\/1471-2105-11-379 (2010).","journal-title":"BMC Bioinformatics"},{"key":"17705_CR38","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1093\/bioinformatics\/14.9.817","volume":"14","author":"D Posada","year":"1998","unstructured":"Posada, D. & Crandall, K. A. MODELTEST: testing the model of DNA substitution. Bioinformatics \n                           14, 817\u2013818 (1998).","journal-title":"Bioinformatics"},{"key":"17705_CR39","doi-asserted-by":"publisher","unstructured":"He, Z. et al. Evolviewv2: an online visualization and management tool for customized and annotated phylogenetic trees. Nucleic Acids Res \n                           44, W236\u2013241, https:\/\/doi.org\/10.1093\/nar\/gkw370 (2016).","DOI":"10.1093\/nar\/gkw370"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-017-17705-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-017-17705-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-017-17705-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,23]],"date-time":"2022-12-23T16:38:54Z","timestamp":1671813534000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-017-17705-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12,15]]},"references-count":39,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2017,12]]}},"alternative-id":["17705"],"URL":"https:\/\/doi.org\/10.1038\/s41598-017-17705-3","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,12,15]]},"assertion":[{"value":"14 July 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 November 2017","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 December 2017","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"17672"}}